Connect with us

Biotech

Exports of Medicines Increased by 1.6% in the First Semester

During this first half of the year, Switzerland has fallen as the leading supplier of Spanish pharmaceuticals, giving way to the United States in first position, with €3.26 billion. In second position was Germany, with sales of 1.73 billion, followed by the Swiss Confederation, with €1.11 billion. Belgium is the largest destination for Spanish exports of medicines, maintaining the position from a year ago.

Published

on

Exports of medicines maintain the rate. During the first six months of the year, the sale of pharmaceuticals from Spain abroad has increased by 1.6% compared to the same period of the previous year, according to data published today by Icex Expaña Exports and Investments. In total, exports have reached a value of €12.5 billion.

The slight increase occurs after a start to the year with strong increases but after a second quarter with falls in sales. From January to March, sales increased every month. In January, exports grew by 8.4%, to €1.65 billion, while in February they shot up 31.8%, to €2.7 billion.

In the third month of the year, the sale of pharmaceutical products abroad registered the highest number of the year in absolute terms, with €2.7 billion, which represented a year-on-year increase of 10.3%.

However, April recorded the biggest drop of the year, with a drop in exports of 20.1%, up to 1.3 billion. In May, the decrease moderated, recoiling by 12.2%, to €1.98 billion. In June, exports of pharmaceutical products stood at €1.74 billion, 13.6% less than a year ago.

Read more about the exports of medicines and find the most important business news of the day with the Born2Invest mobile app.

Despite the fall in the second quarter, exports of medicines have managed to reach their record in the first half of the year, following the trend of the Spanish economy

Spanish exports in the first half of the year reached their all-time high after growing by 4.7% in the first half of the year, up to €199.95 billion.

However, imports of medicines are below those registered a year ago. In the first semester, drug imports reached €1.9 billion, compared to €13.11 billion a year ago, 9.2% less.

Imports have registered year-on-year falls in the first five months of the year, and have only registered a positive rate in June, with a growth of 24.7%, up to €2.15 billion.

During this first half of the year, Switzerland has fallen as the leading supplier of Spanish pharmaceuticals, giving way to the United States in first position, with €3.26 billion. In second position was Germany, with sales of 1.73 billion, followed by the Swiss Confederation, with €1.11 billion.

In the list of clients, Belgium is the largest destination for Spanish exports of medicines, maintaining the position from a year ago, with 4.8 billion. In second position is Switzerland, with 2.15 billion, and Germany, with €1.07 billion.

__

(Featured image by jnittymaa0 via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Michael Jermaine Cards is a business executive and a financial journalist, with a focus on IT, innovation and transportation, as well as crypto and AI. He writes about robotics, automation, deep learning, multimodal transit, among others. He updates his readers on the latest market developments, tech and CBD stocks, and even the commodities industry. He does management consulting parallel to his writing, and has been based in Singapore for the past 15 years.